SABCS 2021 | Efficacy of TKIs in the treatment of HER2+ breast cancer with or without brain mets

Diogo Martins-Branco, MD, MSc, Institut Jules Bordet and Université Libre de Bruxelles (ULB), Brussels, Belgium, reports on the findings of a systematic review which aimed to assess the clinical outcomes of HER2+ metastatic breast cancer patients with or without brain metastases treated with TKI-containing regimens vs. those treated with non-TKI-containing regimens. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.